97 related articles for article (PubMed ID: 17596532)
1. Lipotoxic and inflammatory phenotypes in rats with uncontrolled metabolic syndrome and nephropathy.
Dominguez J; Wu P; Packer CS; Temm C; Kelly KJ
Am J Physiol Renal Physiol; 2007 Sep; 293(3):F670-9. PubMed ID: 17596532
[TBL] [Abstract][Full Text] [Related]
2. Renal injury: similarities and differences in male and female rats with the metabolic syndrome.
Dominguez JH; Wu P; Hawes JW; Deeg M; Walsh J; Packer SC; Nagase M; Temm C; Goss E; Peterson R
Kidney Int; 2006 Jun; 69(11):1969-76. PubMed ID: 16688121
[TBL] [Abstract][Full Text] [Related]
3. Mycophenolate mofetil ameliorates nephropathy in the obese Zucker rat.
Rodríguez-Iturbe B; Quiroz Y; Shahkarami A; Li Z; Vaziri ND
Kidney Int; 2005 Sep; 68(3):1041-7. PubMed ID: 16105034
[TBL] [Abstract][Full Text] [Related]
4. Prevention of early renal injury by mycophenolate mofetil and its mechanism in experimental diabetes.
Wu YG; Lin H; Qi XM; Wu GZ; Qian H; Zhao M; Shen JJ; Lin ST
Int Immunopharmacol; 2006 Mar; 6(3):445-53. PubMed ID: 16428080
[TBL] [Abstract][Full Text] [Related]
5. Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes.
Utimura R; Fujihara CK; Mattar AL; Malheiros DM; Noronha IL; Zatz R
Kidney Int; 2003 Jan; 63(1):209-16. PubMed ID: 12472785
[TBL] [Abstract][Full Text] [Related]
6. Renal and metabolic effects of tempol in obese ZSF1 rats--distinct role for superoxide and hydrogen peroxide in diabetic renal injury.
Rafikova O; Salah EM; Tofovic SP
Metabolism; 2008 Oct; 57(10):1434-44. PubMed ID: 18803950
[TBL] [Abstract][Full Text] [Related]
7. Treatment of the post-ischaemic inflammatory syndrome of diabetic nephropathy.
Kelly KJ; Dominguez JH
Nephrol Dial Transplant; 2010 Oct; 25(10):3204-12. PubMed ID: 20466672
[TBL] [Abstract][Full Text] [Related]
8. Combined MMF and insulin therapy prevents renal injury in experimental diabetic rats.
Wu X; Zha D; Xiang G; Zhang B; Xiao SY; Jia R
Cytokine; 2006 Dec; 36(5-6):229-36. PubMed ID: 17337203
[TBL] [Abstract][Full Text] [Related]
9. Mycophenolate mofetil slows progression in anti-thy1-induced chronic renal fibrosis but is not additive to a high dose of enalapril.
Krämer S; Loof T; Martini S; Rückert M; Wang Y; Böhler T; Shimizu F; Kawachi H; Neumayer HH; Peters H
Am J Physiol Renal Physiol; 2005 Aug; 289(2):F359-68. PubMed ID: 15769934
[TBL] [Abstract][Full Text] [Related]
10. Synergistic effects of mycophenolate mofetil and losartan in a model of chronic cyclosporine nephropathy.
Yang CW; Ahn HJ; Kim WY; Li C; Jung JY; Yoon SA; Kim YS; Cha JH; Kim J; Bang BK
Transplantation; 2003 Feb; 75(3):309-15. PubMed ID: 12589150
[TBL] [Abstract][Full Text] [Related]
11. Renoprotective effects of combination of angiotensin converting enzyme inhibitor with mycophenolate mofetil in diabetic rats.
Wu YG; Lin H; Qian H; Zhao M; Qi XM; Wu GZ; Lin ST
Inflamm Res; 2006 May; 55(5):192-9. PubMed ID: 16830106
[TBL] [Abstract][Full Text] [Related]
12. Postischemic inflammatory syndrome: a critical mechanism of progression in diabetic nephropathy.
Kelly KJ; Burford JL; Dominguez JH
Am J Physiol Renal Physiol; 2009 Oct; 297(4):F923-31. PubMed ID: 19656916
[TBL] [Abstract][Full Text] [Related]
13. Human apolipoprotein B transgenic SHR/NDmcr-cp rats show exacerbated kidney dysfunction.
Asahina M; Shimizu F; Ohta M; Takeyama M; Tozawa R
Exp Anim; 2015; 64(3):313-21. PubMed ID: 25912321
[TBL] [Abstract][Full Text] [Related]
14. Anti-LOX-1 therapy in rats with diabetes and dyslipidemia: ablation of renal vascular and epithelial manifestations.
Dominguez JH; Mehta JL; Li D; Wu P; Kelly KJ; Packer CS; Temm C; Goss E; Cheng L; Zhang S; Patterson CE; Hawes JW; Peterson R
Am J Physiol Renal Physiol; 2008 Jan; 294(1):F110-9. PubMed ID: 17989113
[TBL] [Abstract][Full Text] [Related]
15. Effects of mycophenolate mofetil, valsartan and their combined therapy on preventing podocyte loss in early stage of diabetic nephropathy in rats.
Zhang Y; Chen B; Hou XH; Guan GJ; Liu G; Liu HY; Li XG
Chin Med J (Engl); 2007 Jun; 120(11):988-95. PubMed ID: 17624267
[TBL] [Abstract][Full Text] [Related]
16. Mycophenolate mofetil prevents salt-sensitive hypertension resulting from angiotensin II exposure.
Rodríguez-Iturbe B; Pons H; Quiroz Y; Gordon K; Rincón J; Chávez M; Parra G; Herrera-Acosta J; Gómez-Garre D; Largo R; Egido J; Johnson RJ
Kidney Int; 2001 Jun; 59(6):2222-32. PubMed ID: 11380825
[TBL] [Abstract][Full Text] [Related]
17. Mycophenolate mofetil prevents the progressive renal failure induced by 5/6 renal ablation in rats.
Romero F; Rodríguez-Iturbe B; Parra G; González L; Herrera-Acosta J; Tapia E
Kidney Int; 1999 Mar; 55(3):945-55. PubMed ID: 10027931
[TBL] [Abstract][Full Text] [Related]
18. Mycophenolate mofetil administration reduces renal inflammation, oxidative stress, and arterial pressure in rats with lead-induced hypertension.
Bravo Y; Quiroz Y; Ferrebuz A; Vaziri ND; Rodríguez-Iturbe B
Am J Physiol Renal Physiol; 2007 Aug; 293(2):F616-23. PubMed ID: 17567935
[TBL] [Abstract][Full Text] [Related]
19. Distinct Endothelial Cell Responses in the Heart and Kidney Microvasculature Characterize the Progression of Heart Failure With Preserved Ejection Fraction in the Obese ZSF1 Rat With Cardiorenal Metabolic Syndrome.
van Dijk CG; Oosterhuis NR; Xu YJ; Brandt M; Paulus WJ; van Heerebeek L; Duncker DJ; Verhaar MC; Fontoura D; Lourenço AP; Leite-Moreira AF; Falcão-Pires I; Joles JA; Cheng C
Circ Heart Fail; 2016 Apr; 9(4):e002760. PubMed ID: 27056881
[TBL] [Abstract][Full Text] [Related]
20. Mycophenolate mofetil prevents arteriolopathy and renal injury in subtotal ablation despite persistent hypertension.
Tapia E; Franco M; Sánchez-Lozada LG; Soto V; Avila-Casado C; Santamaría J; Quiroz Y; Rodríguez-Iturbe B; Herrera-Acosta J
Kidney Int; 2003 Mar; 63(3):994-1002. PubMed ID: 12631080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
